Ligand Pharmaceuticals

LGND · NASDAQ

$306.40+$9.12 (+3.07%)TodayMarket closed · Oct 20, 7:59 PM ET

Prev close $297.28

LGND analyst rating

BuyConsensus of 10 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy10
Hold0
Underperform0
Sell0

12-month price target · 14 analysts

Average $351.14 (+14.6% upside)

Low: $249.47
Now: $306.40
High: $416.85

Upgrades and downgrades

The latest rating actions, newest first

LGND analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Barclays	Sep 25, 2026	Initiates	Overweight	$345.00	53%
HC Wainwright & Co.	Sep 24, 2026	Maintains	Buy	$358.00	40%
Citigroup	Sep 23, 2026	Maintains	Buy	$390.00 → $397.00	42%
Leerink Partners	Aug 14, 2026	Initiates	Outperform	$330.00	71%
RBC Capital	Aug 7, 2026	Maintains	Outperform	$340.00 → $345.00	56%
HC Wainwright & Co.	Aug 6, 2026	Maintains	Buy	$289.00 → $358.00	40%
Oppenheimer	Aug 3, 2026	Maintains	Outperform	$285.00 → $326.00	45%
Citigroup	Jul 21, 2026	Initiates	Buy	$387.00	42%
RBC Capital	Jul 15, 2026	Maintains	Outperform	$262.00 → $340.00	56%
B of A Securities	Jul 9, 2026	Maintains	Buy	$266.00 → $388.00	64%

The case for and against

Updated Oct 17, 2026

Bull case

Ligand Pharmaceuticals is attractive fundamentally because its high-margin royalty-and-Captisol model converts a broad portfolio of commercial and late-stage assets into recurring cash flow while limiting operating risk. Q2/26 total revenue of $63.7MM rose 34% y/y, adjusted core EPS of $2.37 beat expectations, and management raised the low end of 2026 EPS guidance to $9.00–$9.50 while reaffirming $270–$310MM in total revenue. Its outlook is further supported by roughly $1 billion in deployable capital, 200+ assets after the XOMA acquisition, and multiple growth catalysts including 7 pivotal readouts expected by the end of 2027 and strong royalty momentum from products like FILSPARI and Ohtuvayre.

Bear case

Ligand Pharmaceuticals is viewed negatively because its valuation depends heavily on partnered assets and early-stage programs that still face substantial clinical and commercial uncertainty, including inconclusive trials, poor reimbursement, and weak traction from marketed drugs. Its revenue base remains exposed to concentrated royalty contributors and Captisol sales, both of which could be pressured by competition, manufacturing or IP issues, and slower-than-expected product performance, while acquisitions and deal-making add execution risk. The cited AVC-201 data are still from a small, short-follow-up Phase 1a study of 17 patients, so durability and commercial relevance remain unproven despite some early responses in a historically difficult AML setting.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.